Hint mode is switched on Switch off

Acumen Pharmaceuticals, ordinary share
ABOS, US00509G2093

Add a stock to WL
Choose all Reset all
Acumen Pharmaceuticals, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Acumen Pharmaceuticals is a discovery stage biotechnology company focused on discovering and developing in partnership with leading pharmaceutical companies best in class therapeutics and diagnostics for Alzheimer's disease. Acumen owns or has exclusive license to a ...
Acumen Pharmaceuticals is a discovery stage biotechnology company focused on discovering and developing in partnership with leading pharmaceutical companies best in class therapeutics and diagnostics for Alzheimer's disease. Acumen owns or has exclusive license to a broad set of patents, related intellectual property and drug development capabilities relating to amyloid beta soluble oligomers, now widely believed to be an underlying cause of Alzheimer's disease. Acumen is partnered with Merck & Co. for the development of certain monoclonal antibody therapeutics. NeuroVentures LLC and Biotechnology Value Fund LP have made investments in the company.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Acumen Pharmaceuticals Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ABOS
  • Placement
    01.07.2021
  • Lock up period
    180
  • Number of papers
    9,999,999
  • Volume of raised funds
    160 mln USD
  • Placement share
    25.87%
  • Final placement price
    16 USD
  • Price change since placement date
    -86.31%
  • By capitalization
    618.43 mln USD
Other placements of the issuer
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ABOS
  • Placement
    20.07.2023
  • Lock up period
    180
  • Number of papers
    57,799,255
  • Volume of raised funds
    130 mln USD
  • Placement share
    29.02%
  • Final placement price
    7.75 USD
  • Price change since placement date
    -71.74%
  • By capitalization
    447.94 mln USD

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
II q eng
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

13/03/2026 Acumen Pharmaceuticals: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Regulation Fd Disclosure, Financial Statements And Exhibits
15/07/2025 Acumen Pharmaceuticals: Regulation Fd Disclosure, Financial Statements And Exhibits
13/05/2025 Acumen Pharmaceuticals: Of This Report (including Exhibit 99.1) Is Being Furnished And Shall Not Be Deemed “filed” For Purposes Of Section18 Of The Securities Exchange Act Of 1934, As Amended (the “, Regulation Fd Disclosure, Financial Statements And Exhibits
27/03/2025 Acumen Pharmaceuticals: Of This Report (including Exhibit 99.1) Is Being Furnished And Shall Not Be Deemed “filed” For Purposes Of Section18 Of The Securities Exchange Act Of 1934, As Amended (the “, Regulation Fd Disclosure
12/11/2024 Acumen Pharmaceuticals: Of This Report (including Exhibit 99.1) Is Being Furnished And Shall Not Be Deemed “filed” For Purposes Of Section18 Of The Securities Exchange Act Of 1934, As Amended (the “, regulation Fd Disclosure
All organization news

Holders

Industry Leaders

Registration is required to get access.